AIM ImmunoTech Inc is trading at $0.78 (13.4% down) as the stock experiences a pullback following a significant two-day surge tied to its pancreatic cancer program.
- The recent momentum was driven by news that the company completed enrollment early in its Phase 2 DURIPANC pancreatic cancer trial, which sent shares up more than 120% on June 1.
- In the absence of fresh company news this morning, today's decline appears to be driven by profit-taking and volatility following the massive catalyst-driven rally.